S 832 119th Congress Senate In Committee

EPIC Act of 2025

Latest action: Read twice and referred to the Committee on Finance. · Mar 4, 2025

View full text on Congress.gov ↗ Policy area: Health

Legislative Summary

Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program. The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation beginning in 2028.

Source: Congressional Research Service (CRS).

Sponsor
Sen. Tillis, Thomas [R-NC]
Independent · NC
Cosponsors (7)
Sen. BuddSen. BlackburnSen. DainesSen. LankfordSen. CurtisSen. MarshallSen. Banks

Track S 832 in BallotBox360

Get real-time bill updates, floor vote alerts, and AI-powered summaries — all in one app.

Download on iOS Open Web App